Last reviewed · How we verify
Levodopa Benserazide Madopar
Levodopa Benserazide Madopar is a Dopamine precursor with peripheral decarboxylase inhibitor Small molecule drug developed by IRCCS San Raffaele Roma. It is currently FDA-approved for Parkinson's disease.
Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa to prevent side effects.
Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa to prevent side effects. Used for Parkinson's disease.
At a glance
| Generic name | Levodopa Benserazide Madopar |
|---|---|
| Sponsor | IRCCS San Raffaele Roma |
| Drug class | Dopamine precursor with peripheral decarboxylase inhibitor |
| Target | Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Levodopa crosses the blood-brain barrier and is converted to dopamine by aromatic amino acid decarboxylase, restoring dopamine levels in Parkinson's disease patients. Benserazide is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa to dopamine outside the central nervous system, allowing more levodopa to reach the brain and reducing peripheral adverse effects like nausea and cardiovascular symptoms.
Approved indications
- Parkinson's disease
Common side effects
- Nausea
- Dyskinesia
- Orthostatic hypotension
- Dizziness
- Hallucinations
- Insomnia
Key clinical trials
- Evaluation of the Effects of Levodopa-Benserazide Drug Combination on Periodontal Status in Patients With Parkinson's Disease
- Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
- Dopamine and Brain Computer Interface (EARLY_PHASE1)
- Relative Bioavailability Study of HRG2010 in Healthy Subjects (PHASE1)
- Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease (PHASE2)
- Dopamine, Reward Learning and Sex Hormones (NA)
- Levodopa Benserazide Generic Formulation Versus the Originator (PHASE4)
- Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levodopa Benserazide Madopar CI brief — competitive landscape report
- Levodopa Benserazide Madopar updates RSS · CI watch RSS
- IRCCS San Raffaele Roma portfolio CI
Frequently asked questions about Levodopa Benserazide Madopar
What is Levodopa Benserazide Madopar?
How does Levodopa Benserazide Madopar work?
What is Levodopa Benserazide Madopar used for?
Who makes Levodopa Benserazide Madopar?
What drug class is Levodopa Benserazide Madopar in?
What development phase is Levodopa Benserazide Madopar in?
What are the side effects of Levodopa Benserazide Madopar?
What does Levodopa Benserazide Madopar target?
Related
- Drug class: All Dopamine precursor with peripheral decarboxylase inhibitor drugs
- Target: All drugs targeting Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide)
- Manufacturer: IRCCS San Raffaele Roma — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Parkinson's disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing